A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

Autor: Infante, Jeffrey R., Papadopoulos, Kyriakos P., Bendell, Johanna C., Patnaik, Amita, Burris, Howard A., III, Rasco, Drew, Jones, Suzanne F., Smith, Lon, Cox, Donna S., Durante, Michael, Bellew, Kevin M., Park, Joohyun (Jennifer), Le, Ngocdiep T., Tolcher, Anthony W.
Zdroj: In European Journal of Cancer June 2013 49(9):2077-2085
Databáze: ScienceDirect
Externí odkaz: